<DOC>
	<DOCNO>NCT01546337</DOCNO>
	<brief_summary>Anemia common among cancer patient treatment choice Erythropoiesis-Stimulating Agents ( ESAs ) . However , patient respond treatment . The purpose study evaluate predictive value endogenous erythropoietin rate response erythropoietin beta . First , confirm predictive value endogenous erythropoietin observe / predict ratio response . Then confirm establish optimal value ratio .</brief_summary>
	<brief_title>Search Predictive Markers Efficacy ESAs Patients With Non-myeloid Malignancies Myelodysplastic Syndrome</brief_title>
	<detailed_description>Anemia common among cancer patient treatment choice Erythropoiesis-Stimulating Agents ( ESAs ) . However , patient respond treatment . Thus , 50-60 % patient multiple myeloma non-Hodgkin lymphoma respond ESAs . The purpose study evaluate predictive value endogenous erythropoietin rate response erythropoietin beta . First , confirm predictive value endogenous erythropoietin observe / predict ratio response . Then confirm establish optimal value ratio .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients 18 patient nonmyeloid haemopathy receive chemotherapy myelodysplastic syndrome indication ESAs therapy Hb &lt; 11g/dl uncontrolled hypertension anemia due deficiency pregnant lactate woman patient receive treatment erythropoiesisactivating factor two month precede inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>non-myeloid haemopathy</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>Erythropoiesis stimulating agent</keyword>
	<keyword>predictive marker</keyword>
</DOC>